ERBB2 and triple-negative breast carcinoma: Le Scodan et al. distinguished between HER2 positive population treated with trastuzumab and triple negative breast cancer [13], while Sperduto et al.[12] and Niwinska et al.[14] distinguished between luminal A, B, HER2, and basal tumors.